Google to loosen pharma ad rules for AdMob authorized buyers

Google will update its Pharmaceutical policy for AdMob Authorized Buyers in January, allowing prescription drug and prescription drug service ads in select markets without Google certification while clarifying what remains strictly prohibited.

What’s changing. The policy will be renamed “Pharmaceutical products and services” and updated to let Authorized Buyers promote prescription drugs and prescription drug services in select countries where local law allows, without the Google certification normally required in Google Ads.

• While access is expanding, the rules are not loosening. The policy language is being reorganized to improve clarity and readability, not to relax enforcement.

Why we care. This update expands access to pharmaceutical inventory without Google certification, opening new reach and adding competitive pressure in programmatic auctions. It also shifts more compliance responsibility to advertisers, raising the risk of violations if geo-targeting and creative controls aren’t tightly managed. Even non-pharma advertisers may feel the impact as increased pharma demand can affect pricing, brand safety, and placement strategies.

What’s still banned. These types of ads remain prohibited across Google Partner Inventory:

• Clinical trials.
• Miracle cures.
• Unapproved supplements.
• Illegal drugs.
• Drug paraphernalia.
• Addiction treatment and recovery services.
• Crisis hotlines.
• Speculative or experimental medical treatments (including stem cell and gene therapies)

Between the lines. Google is widening access while pushing responsibility downstream. By removing certification requirements for Authorized Buyers but keeping strict geographic and content controls, Google places compliance risk squarely on buyers and publishers.

What to do now. App publishers using AdMob should review category blocking and ad controls to prevent unwanted pharma ads, especially as more inventory becomes eligible. Buyers should prepare for country-by-country enforcement and carefully audit creatives.

Bottom line. Google is opening the door wider for pharmaceutical advertising in programmatic environments — but the rules are still complex, localized, and unforgiving for those who get them wrong.